Zee Laboratory filed a petition under Section 482 Cr.P.C. before the Punjab and Haryana High Court seeking to quash a complaint, summoning order, and all consequential proceedings arising from a 2018 complaint filed by the Union of India. The complaint alleged that a sample of the drug Zextil 200 (Cefpodoxime tablet IP), drawn from Civil Hospital Nawanshahr in August 2014, was found 'Not of Standard Quality' as its dissolution results (38.54%–46.51% w/w) fell far below the prescribed minimum of 70% w/w, potentially causing grievous hurt or death to patients. The petitioner argued that Section 27(c) of the Drugs and Cosmetics Act, 1940 (relating to spurious drugs) was not made out since the drug was merely found substandard, not spurious, and that the applicable offence under Section 27(d) carries a maximum sentence of two years, making the complaint time-barred under Section 468(2) Cr.P.C. as it was filed more than three years and eight months after the test report. The respondent-Union of India contended that the low dissolution rate was likely to cause grievous hurt or death, justifying the invocation of Section 27(c), and denied any delay. The judgment text as provided does not record a final operative order, as it concludes mid-way through reproducing the statutory provisions.